CLINICAL_TRIALS
trial_result
· 2018-06-12
Clinical Trial Update: Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma [Phase 2]
Summary
Phase 2 study evaluating IMO-2055 for metastatic or locally recurrent clear cell renal cell carcinoma has completed and results are posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-06-12